Clinical Trial Search

Primary: Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) — 14.3; 6.0 Months

Primary: Effect of Lanreotide on Gastrointestinal Motility as Measured by Smart Pill — 371.52; 392; 4767; 5159 minutes — p=0.07

Primary: Symptom Control (Diarrhea/Flushing) Using a Patient Symptom Diary — 3; 9; 32 participants

Primary: Proportion of Patients Who Are Biochemically Controlled Throughout the RCT Phase — 50; 37 Participants

Primary: Percentage of Patients Who Achieved Clinical Symptom Improvement by Randomization Stratum and Treatment. — 13.5; 28.2; 100; 20.0 Percentage of Participants

Primary: Change in Insulin Basal Level — -24.37; -29.60 pmol/L — p=<0.001

Primary: Percentage of Patients With Relevant Reduction in Pituitary Tumour Volume (as Measured by MRI) From Baseline Volume (Visit 1) to Week 48 (After 12 Injections at Visit 5)…

Primary: Core Phase: Percentage of Participants With Mean GH < 1 g/L and IGF-1 < ULN at Week 36 by Previous Treatment and Overall — 14.6; 13.8; 15.1; 14.6 Percentage of…

Primary: IGF-1 Level on Sandostatin LAR — 336; 186; 487 ng/mL — p=<0.05

Primary: Pharmacokinetic (PK) Profile of Octreotide After Each Injection of CAM2029 as Compared With Baseline PK for Sandostatin® Long-acting Release (LAR®) AUC — 6.23; 24.1…

Primary: Overall Response Rate (ORR) — 1; 8; 8; 3 Participants

Primary: Percentage of Days With Subcutaneous Octreotide as Rescue Medication — 33.72; 48.49 Percentage of days — p=0.0165

Primary: Efficacy of Axitinib in Terms of PFS (Investigator Assessment) — 17.2; 13.1 months — p=0.324

Primary: Sensitivity of 64Cu-DOTATATE PET-CT Imaging for Detection of Somatostatin Receptor Positive SSTR (+) Tumor — 30; 3 Participants

Primary: The Percentage of Participants With Complete Response (CR) at 8 Months — 25; 0; 9.4 percent

Primary: To Determine the Biodistribution of [18F] Following Single I.V Administration of [18F]-FET-βAG-TOCA Injection in Patients With a Histological Diagnosis of NET. — 0.002…

Primary: Disease Control Rate (DCR) — 0; 0; 9 Participants

Primary: Progression-Free Survival (PFS) — 14.2 months

Primary: Progression-free Survival (PFS) at One Year — 11 months

Primary: To Measure Safety of 68Ga-DOTATOC Positron Emission Tomography (PET) by Measuring the Number of Adverse Events Related to the Investigational Radiopharmaceutical Agent…

Primary: Percentage of Responders at the End of the Core Treatment Period — 86.9; 66.7; 40.4; 64.9 Percentage of responders

Primary: Percentage of Participants With a Reduction of Mean GH Levels to < 2.5 µg/L and Normalization of Sex- and Age-adjusted IGF-1. — 15.4; 20.0; 0 percentage of participants…

Primary: Four-month Progression-free Survival Rate — 78.5 percentage of participants — p=<0.001

Primary: Median Progression Free Survival (PFS) — 5.6; 8.3 months

Primary: Progression Free Survival (PFS) — NA; 8.5 months — p=<0.0001

Primary: Mean Pain Scores at 3 Months — 2.4; 2.4; 1.9; 1.9 scores on a scale

Primary: Number of Participants With Treatment Success From Day 10 to Day 13 — 12; 9; 19; 13 Participants

Primary: Percentage of Participants With a Reduction of Mean GH Level to <2.5 μg/L and the Normalization of IGF-1 — 31.3; 19.2; 39.4; 21.8 Percentage of Participants — p=0.007

Primary: Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration Period — 57.9 percentage of subjects…

Primary: Number of Participants Characterized by Abnormal or Negative Uptake — 4; 3; 6 Participants